StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $3.04 | $2.94 | -3.29% | 1.2M |
| 05-12 | $2.93 | $2.83 | -3.41% | 0.7M |
| 05-13 | $2.82 | $2.86 | +1.42% | 0.5M |
| 05-14 | $2.88 | $2.86 | -0.69% | 0.6M |
| 05-15 | $2.82 | $2.75 | -2.48% | 0.6M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Annual 2020 2020-12-31 | Annual 2020 2020-09-30 | Annual 2020 2020-06-30 | Annual 2020 2020-03-31 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
Operating Income | $-69.57M | $-46.39M | $-27.91M | $-12.88M |
Net Income | $-67.25M | $-44.63M | $-14.57M | $-12.14M |
EPS (Diluted) | $-2.05 | $-1.42 | $-0.92 | $-0.51 |
Total Assets | $329.67M | $346.44M | $349.45M | $362.80M |
Total Liabilities | $21.91M | $19.09M | $6.33M | $7.54M |
Cash & Equivalents | $34.60M | $56.20M | $63.98M | $357.19M |
Free Cash Flow OCF − CapEx | $-52.29M | $-36.41M | $-24.91M | $-11.32M |
Shares Outstanding | 36.08M | 35.96M | 35.91M | 35.91M |
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.